Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2017

View Archived Issues

mGlu4 receptor found as a target for treating maladaptive impulsivity

PhoenixMD reports favorable preclinical data on RSK inhibitor for TNBC

FDA advisory committee recommends approval of Pfizer's epoetin alfa biosimilar

Orexin OX2 receptor agonist as promising new therapeutic approach for narcolepsy-cataplexy symptoms

Hovione begins phase I study of HY-02

Lundbeck patents P2X7 receptor antagonists

Hubei Biological Medicine Industrial Technology Institute and collaborator divulge ALK inhibitors

Jiangsu Hansoh Pharmaceutical Group identifies compounds against HCV

Merck KGaA discovers PARP-1 and TANK1/2 inhibitors

Roche presents equilibrative nucleoside transporter 1 inhibitors

Ciprofloxacin DPI benefit not significant in phase III bronchiectasis trial

FDA grants priority review to axicabtagene ciloleucel BLA

FDA grants approval for expanded use of Zykadia in first-line ALK-positive metastatic NSCLC

FDA issues complete response letter for SUN-101/eFlow

Valerion Therapeutics begins recruitment in phase I/II trial of VAL-1221

ENaC inhibitor AZD-5634 shows reduced potential for side effects in first-in-human study

Targeting KLF5 for the treatment of colorectal cancer

FDA grants orphan designation to liposome irinotecan injection for small cell lung cancer

Model recapitulates features of chronic human empyema

Galderma's resiquimod named U.S. orphan drug for cutaneous T-cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...